DUBLIN--(BUSINESS WIRE)--The "Wet AMD- Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
"Wet AMD-Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Wet AMD. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 75+ products along with 65+ companies involved.
Products covered by Phase
- Phase III, Phase II and Phase I
- Pre-clinical and Discovery
- Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Wet AMD
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Wet AMD
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
Companies Mentioned
- Aciont
- Alimera sciences
- Allegro Opthalmics
- Allergan
- Bayer
- BioMAS
- Boehringer Ingelheim
- Charlesson
- Clanotech
- Coherus Biosciences
- CoMentis
- Daiichi Sankyo
- Exonate
- Genera Corporation
- GenVec
- GlaxoSmithKline
- Jerini Opthalmic
- Kalos therapeutics
- Kodiac Sciences
- Light Sciences
- Lpath
- MeiraGTx
- Neurotech
- Novartis
- Ocugen
- OPKO Health
- Opthea
- PanOptica
- Pfizer
- pSivida
- RXI Pharmaceuticals
- S & I Ophthalmic
- Sanofi
- ThromboGenics
- Tyrogenex
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rq6dx5/wet_amd_pipeline?w=4
